7 active not recruiting, 4 completed, 3 recruiting, 1 terminated. 6 Phase 1, 3 Early Phase 1, 3 Phase 2, 1 Not applicable.
Follow this condition Literature Review of Stage IIIA Ovarian Cancer AJCC v8 trials Research Report on Stage IIIA Ovarian Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs - Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8 | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2023-12-15 | 2023-11-22 | |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Active not recruiting | University of Southern California | 173 | 2021-11-24 | 2026-10-05 | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer Uterine lavage, or a wash of the womb, Blood sample, Pap smear - Ovarian Neoplasms, Ovarian Epithelial Carcinoma | Recruiting | Massachusetts General Hospital | 250 | 2020-04-13 | 2025-09-16 | |
| A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors TRPV6 Calcium Channel Inhibitor SOR-C13 - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2019-07-29 | 2023-11-18 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study Biospecimen Collection - Advanced Malignant Neoplasm, Advanced Melanoma | Completed | National Cancer Institute (NCI) | 64 | 2019-07-16 | 2026-02-04 | |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Chemotherapy, Olaparib, Therapeutic Conventional Surgery - BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-06-07 | 2026-08-12 |
| Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Early Phase 1 | Completed | Mayo Clinic | 197 | 2019-06-06 | 2024-08-14 |
| Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer Chemotherapy, Functional Assessment, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Active not recruiting | SWOG Cancer Research Network | 1336 | 2019-05-14 | 2026-10-02 | |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer Biospecimen Collection, Laboratory Biomarker Analysis, Lavage - High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8 | Not applicable | Terminated | University of Washington | 52 | 2018-11-16 | 2024-01-17 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Laboratory Biomarker Analysis, Pembrolizumab - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 21 | 2018-03-08 | 2026-04-03 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
Ovarian Neoplasms (16) · Fallopian Tube Neoplasms (7) · Colorectal Neoplasms (4) · Prostatic Neoplasms (4) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Urogenital Neoplasms (2) · Uterine Cervical Neoplasms (2) · Bone Neoplasms (1)
Adnexal Diseases (16) · Endocrine Gland Neoplasms (16) · Endocrine System Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases (16) · Genital Diseases, Female (16) · Genital Neoplasms, Female (16) · Gonadal Disorders (16) · Neoplasms by Site (16) · Urogenital Diseases (16) · Ovarian Diseases (15) · Neoplasms (14) · Urogenital Neoplasms (14) · Fallopian Tube Diseases (7)
Taxes (3) · Drug Therapy (2) · Paclitaxel (2) · Papanicolaou Test (2) · Specimen Handling (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Blood Specimen Collection (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Cytoreduction Surgical Procedures (1) · Decitabine (1)
M.D. Anderson Cancer Center (4) · Roswell Park Cancer Institute (2) · City of Hope Medical Center (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Precigen, Inc (1) · Rutgers, The State University of New Jersey (1) · SWOG Cancer Research Network (1) · University of Southern California (1) · University of Washington (1)
United States (16) · Chile (1) · Colombia (1) · Mexico (1) · Puerto Rico (1)
Amy R. Lankford, PhD (1) · Apostolia M Tsimberidou (1) · Barbara S. Norquist (1) · Christos Patriotis, PhD (1) · Emese Zsiros, MD, PhD (1) · Eugenia Girda, MD (1) · Floor Backes, MD (1) · Jewel Samadder, M.D. (1) · Kimberly Miller, PhD (1) · Laleh Melstrom (1) · Meghna S Trivedi (1) · Philip McCarthy, MD (1) · Rosana Risques (1) · S. P Ivy (1) · Shannon N Westin (1)
P30CA014089 (1), P30CA016056 (1), P30CA033572 (1), P30CA072720 (1), P50CA159981 (1), R01CA164333 (1), R37CA256867 (1), U01CA152990 (1), U2CCA271871 (1), UG1CA189974 (1)